Glaxo Case Pushes U.S. Health Settlements to $6.6 Billion

GlaxoSmithKline Plc, Johnson & Johnson and other drugmakers have paid $6.6 billion this year to settle claims of defrauding U.S. health programs, more than double the amount of 2011, advocacy group Public Citizen said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.